Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glutamatergic System and Response to Clozapine in Patients With Treatment-Resistant Schizophrenia: a Prospective Proton Magnetic Resonance Spectroscopy Study

NCT02714894 is registered in ClinicalTrials.gov with Centre for Addiction and Mental Health as lead sponsor.

NCT NCT02714894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02714894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glutamatergic System and Response to Clozapine in Patients With Treatment-Resistant Schizophrenia: a Prospective Proton Magnetic Resonance Spectroscopy Study
Lead sponsor
Centre for Addiction and Mental Health
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2016
Completion date
July 30, 2022
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia